Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 7/20 | 0.57 |
| ▸ | CHUK | O15111 | 5/20 | 0.46 |
| ▸ | BRD4 | O60885 | 4/20 | 0.45 |
| ▸ | IDH1 | O75874 | 6/20 | 0.39 |
| ▸ | BRAF | P15056 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17895301 | 0.83 | IKBKB (0.59) | IKBKBCHUK | |
| SCHEMBL3496486 | 0.82 | BRD4 (0.39) | IKBKBBRD4IDH1BRAFKDR | |
| SCHEMBL3498026 | 0.82 | BRD4 (0.54) | IKBKBCHUKBRD4 | |
| SCHEMBL17895079 | 0.79 | BRD4 (0.40) | IKBKBCHUKBRD4IDH1BRAF | |
| SCHEMBL17894989 | 0.78 | FYN (0.40) | IKBKBCHUKBRD4 | |
| SCHEMBL17895296 | 0.78 | IKBKB (0.54) | IKBKBCHUKBRD4IDH1BRAF | |
| SCHEMBL17894990 | 0.76 | IKBKB (0.70) | IKBKBCHUK | |
| SCHEMBL2819718 | 0.76 | IKBKB (0.69) | IKBKBCHUK | |
| SCHEMBL19786880 | 0.70 | IKBKB (0.43) | IKBKBCHUKBRD4 | |
| SCHEMBL3495235 | 0.67 | BRD4 (0.52) | IKBKBCHUKBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240789-B1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIV MONTPELLIER (FR) | 2020-07-29 | — | — | EP | disclosed |
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | UNIVERSITE DE MONTPELLIER (FR) | 2020-06-23 | — | — | US | disclosed |
| EP-3240789-A1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | Université de Montpellier (FR) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016107895-A1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIVERSITE DE MONTPELLIER (FR) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | NQO1, NQO2, ABL1 | IKBKB 1832/4885CHUK 1133/4885BRD4 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.